| 李瑞娜.重组人脑利钠肽对急性心肌梗死并心源性休克疗效及预后分析[J].安徽医药,2019,23(4):696-699. |
| 重组人脑利钠肽对急性心肌梗死并心源性休克疗效及预后分析 |
| Efficacy and prognosis of recombinant human brain natriuretic peptide in acute myocardial infarction complicated with cardiogenic shock |
| 投稿时间：2017-07-24 |
| DOI： |
| 中文关键词: 心肌梗死 利钠肽,脑 休克,心源性 肌酸激酶 肌钙蛋白I |
| 英文关键词: Myocardial infarction Natriuretic peptide,brain Shock,cardiogenic Creatine kinase Troponin I |
| 基金项目: |
|
| 摘要点击次数: 1753 |
| 全文下载次数: 589 |
| 中文摘要: |
| 目的探讨重组人脑利钠肽治疗急性心肌梗死(AMI)合并心源性休克病人的临床效果。方法 选取2014年4月至2016年5月河南医学高等专科学校附属医院收治的AMI合并心源性休克的病人86例,采用随机数字表法分为观察组和对照组各43例,两组病人均接受基础治疗,观察组同时应用重组人脑利钠肽治疗,对比两组的临床效果。结果 治疗后24 h、治疗后7 d,观察组病人的收缩压、舒张压水平高于对照组(P<0.05),观察组的心率低于对照组(P<0.05)；治疗前,两组病人的血肌酐(Scr)、血氧饱和度(SPaO2)、左室射血分数(LVEF)、左室舒张末期内径(LVEDD)、肌酸激酶同工酶(CK-MB)、肌钙蛋白I(cTnI)水平差异无统计学意义(P>0.05)；治疗后7 d,观察组病人的SPaO2、LVEF高于对照组(P<0.05),观察组的LVEDD低于对照组(P<0.05),观察组病人的血清CK-MB、cTnI水平低于对照组(P<0.05)。救治过程中,观察组有2例(4.65%)病人死亡,对照组有4例(9.30%)病人死亡,两组的病死率差异无统计学意义(χ2=0.717,P=0.397)；治疗后,为期6个月的随访中,观察组不良心血管事件发生率为7.14%、对照组为15.38%,两组不良心血管事件比较差异无统计学意义(χ2=1.391,P=0.238)。结论 重组人脑利钠肽治疗AMI合并心源性休克病人有利于病人休克的救治,同时减轻心肌损伤,改善心功能。 |
| 英文摘要: |
| Objective To investigate the clinical effects of recombinant human brain natriuretic peptide in patients with acute myocardial infarction (AMI) complicated with cardiogenic shock.Methods Eighty-six patients with AMI and cardiogenic shock admitted to Henan Medical College Affiliated Hospital from April 2014 to May 2016 were selected and assigned into observation group and control group,43 cases in each group,according to the random number table method.Both groups received basic treatment,and the observation group was treated with recombinant human brain natriuretic peptide,and the clinical effects of the two groups were compared.Results At 24 h and 7 days after treatment,the systolic blood pressure and diastolic blood pressure of the observation group were higher than those of the control group (P<0.05),and the heart rate of the observation group was lower than that of the control group (P<0.05).There were no significant differences in serum creatinine (Scr),oxygen saturation (SPaO2),left ventricular ejection fraction (LVEF),left ventricular end-diastolic (LVEDD),creatine kinase isoenzyme (CK-MB),and troponin I (cTnI) levels between the two groups before treatment (P>0.05).Seven days after treatment,the SPaO2 and LVEF of the observation group were higher than those of the control group (P<0.05),and the LVEDD of the observation group was lower than that of the control group (P<0.05).After treatment,the serum levels of CK-MB and cTnI in the observation group were lower than those in the control group (P<0.05).During the treatment,2 patients(4.65%) died in the observation group,and 4 patients(9.30%) died in the control group.There was no significant difference in mortality between the two groups (χ2=0.717,P=0.397); after treatment,the two groups of patients were followed up for 6 months.The incidence of adverse cardiovascular events during the follow-up period was 7.14% in the observation group and 15.38% in the control group.There was no significant difference in adverse cardiovascular events between the two groups (χ2=1.391,P=0.238).Conclusion Recombinant human brain natriuretic peptide in patients with AMI complicated with cardiogenic shock is beneficial to the treatment of patients with shock,while reducing myocardial damage and improving cardiac function. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
